Perry Nisen is a physician scientist with extensive experience in drug discovery and development. He focuses on pre-clinical and clinical companies with particular interest in oncology, neuroscience, and immunology/inflammation. Perry is currently the Executive Chairman of the board of Quanta and a member of the board of directors for XyloCor.
Prior to Perry joining Sofinnova in 2018, he was CEO of the Sanford Burnham Prebys Medical Discovery Institute (SBP). As CEO, Perry was responsible for all aspects of the organization including strategy, operations and performance. Prior to SBP, he held multiple senior leadership positions during his tenure at GlaxoSmithKline (GSK) including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head. When he was the Oncology Therapy Area Head, he was accountable for the Oncology portfolio from target to market and this division was subsequently acquired by Novartis for over $16B. Responsibilities at GSK included all aspects of drug discovery, clinical development, risk/benefit and operations. Before GSK, Perry was the Divisional Vice President, Cancer Research at Abbott Laboratories. Prior to industry, Perry was the Lowe Foundation Professor at the University of Texas Southwestern Medical Center.
Perry holds a BS from Stanford University, and MD/PhD from the Albert Einstein College of Medicine.